Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESPER-6
NCT07595549Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jun 2026
- Primary completion
- May 2028
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of berobenatide in obesity and Overweight (5 arms), sponsored by Pfizer. Primary endpoint: Percent change from baseline in body weight at 72 weeks. Started Jun 2026; status: recruiting.
02
Drugs
berobenatide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07595549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07595549.